About this medicine

Faverin is the verified UK brand. Luvox and Luvox CR are retained US aliases; modified-release products must not be assumed equivalent.

What is this medicine used for?

Childhood use is specifically for OCD, not depression. The leaflet describes OCD treatment from age 8; the SmPC’s paediatric dosing paragraph uses “over 8”. Specialist assessment remains necessary.

The adult indications are major depressive episodes and OCD. Treatment response is reviewed over weeks; continuing OCD treatment requires periodic reassessment, and medication does not replace appropriate psychological treatment.

Which warning signs need help?

Urgent assessment is needed for self-harm thoughts, severe restlessness, seizures, a blistering or peeling rash, or fever with confusion and twitching. Seek urgent advice after excess doses.

MHRA’s October 2026 communication announced the rollout of a prominent boxed warning in UK antidepressant patient leaflets about self-harm and suicidal behaviour, alongside a patient safety card. This UK patient-information measure is not the US FDA Boxed Warning designation. Read the leaflet supplied with your medicine, seek prompt professional help for new or worsening mood or behaviour changes, and do not stop treatment suddenly without advice.

How do I take it safely?

Adult product reference: depression starts at 50 or 100 mg in the evening; OCD starts at 50 mg daily. The maximum is 300 mg daily, with doses above 150 mg divided. Children with OCD have a lower, specialist-managed schedule and 200 mg daily maximum. These are not personal titration instructions.

The childhood OCD schedule starts at 25 mg/day, using the scored tablet as prescribed. Adult and childhood dose-division rules differ. Liver or kidney impairment calls for a low starting dose and closer supervision.

What side effects should I know about?

Nausea, vomiting, headache, sweating, tremor, disturbed sleep and bowel symptoms are recognised. Persistent symptoms deserve review.

MHRA is adding the term post-SSRI sexual dysfunction (PSSD) to patient leaflets describing persistent sexual difficulties after stopping certain antidepressants, including this medicine. Their frequency and causes remain under study. Persistent symptoms deserve support; this does not mean everyone taking the medicine will experience them.

Who needs extra care with this medicine?

Discuss previous mania, epilepsy, bleeding problems, diabetes, glaucoma and liver or kidney disease.

Can it affect my other medicines?

Tizanidine, pimozide and MAO inhibitors are incompatible. Strong CYP1A2/CYP2C19 inhibition affects many medicines, including clozapine and theophylline. Caffeine effects can increase; a pharmacist should check every medicine and supplement.

What check-ups will I need?

Review mood and tolerability early, including unusual agitation. Drug concentrations or other checks may be needed when an interacting medicine is prescribed.

Behavioural change, suicidal thinking and severe restlessness need particular attention early in treatment or after dose changes. Increasing a dose can worsen akathisia—the distressing inability to keep still.

What about pregnancy, breastfeeding and age?

Pregnancy needs an individual decision; the product advises against breastfeeding during treatment. Children treated for OCD need monitoring of behaviour, growth and development.

What if I miss a dose or want to stop?

Avoid abrupt stopping: withdrawal symptoms can occur after missed doses or discontinuation. Agree a gradual reduction and do not double a missed dose.

Switching to or from an MAOI requires a clinician-managed separation period. Withdrawal symptoms can resemble anxiety or relapse; new symptoms after a reduction deserve assessment rather than an automatic dose increase.

How does it work?

Fluvoxamine slows the return of serotonin, a chemical messenger, into the nerve cells that released it. This process is called reuptake; reducing it leaves more serotonin available between cells and changes how they communicate. The action does not establish that depression is caused by a simple serotonin shortage.

How Brain Cells Communicate

Nerve cells use chemical messengers called neurotransmitters to communicate across tiny gaps, known as synapses. Serotonin can attach to receptors, proteins that detect the message and influence the receiving cell. The serotonin transporter, or SERT, carries some serotonin back into the sending cell. This return process, called reuptake, helps regulate how long the message is available.

What is known: Serotonin signaling is regulated partly by reuptake.

What remains uncertain: Mood and repetitive thoughts or behaviours involve more than one chemical messenger.

Serotonin and SERT

A transporter across a membrane, with the sending-cell interior above and released messenger outside below. The uptake direction is upward. Serotonin: The messenger is shown outside the sending cell. SERT: This transporter returns serotonin from outside into the sending cell. Return into the cell: The arrow shows transport direction, without a measured rate.
  1. Serotonin

    The messenger is shown outside the sending cell.

  2. SERT

    This transporter returns serotonin from outside into the sending cell.

  3. Return into the cell

    The arrow shows transport direction, without a measured rate.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

The SERT transporter returns serotonin from outside the nerve cell into the cell. This is a separate transport system.

Serotonin signaling is regulated partly by reuptake. Simplified illustration of the process; individual responses vary.
About this illustration

Nerve-cell signal; Receptor or transporter; Network activity. Mood and repetitive thoughts or behaviours involve more than one chemical messenger.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

Fluvoxamine inhibits SERT, meaning it reduces the transporter’s activity and slows serotonin recycling. This is why it is described as a selective serotonin reuptake inhibitor, or SSRI. Its effects on communication are thought to contribute to improvements in mood or obsessive-compulsive symptoms: obsessions are unwanted, recurring thoughts or urges, while compulsions are repetitive actions or mental rituals a person feels driven to perform. The amount of transport inhibition does not directly measure an individual’s improvement.

What is known: Fluvoxamine inhibits serotonin reuptake.

What remains uncertain: Changes in transport cannot by themselves measure improvement in mood or compulsive symptoms.

Fluvoxamine and SERT

A membrane transporter with uptake reduced; messenger remains outside below the membrane. The separate terracotta symbol denotes a medicine, not its molecular shape. Serotonin: The messenger is shown outside the sending cell. SERT: This transporter returns serotonin from outside into the sending cell. Fluvoxamine: uptake inhibited: The interrupted arrow names the action; the symbol is not a molecular shape or binding position.
  1. Serotonin

    The messenger is shown outside the sending cell.

  2. SERT

    This transporter returns serotonin from outside into the sending cell.

  3. Fluvoxamine: uptake inhibited

    The interrupted arrow names the action; the symbol is not a molecular shape or binding position.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Fluvoxamine inhibits neuronal serotonin reuptake. The precise link between this action and improvement in OCD is not established.

Fluvoxamine inhibits serotonin reuptake. Simplified illustration of the process; individual responses vary.
About this illustration

Fluvoxamine; Molecular actions; Clinical effects. Changes in transport cannot by themselves measure improvement in mood or compulsive symptoms.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

The liver processes fluvoxamine, and the amount in the blood can rise more than proportionally as the dose increases. This is called nonlinear exposure: a change in dose does not always produce a matching change in the amount of medicine reaching the body. Fluvoxamine also inhibits several CYP enzymes, proteins that help process other medicines, which can increase the levels of those medicines. Other medicines and differences in liver processing therefore matter when interpreting a fluvoxamine blood level.

What is known: Fluvoxamine can affect drug-processing enzymes as well as serotonin transport.

What remains uncertain: A drug level alone does not predict the overall balance of benefits and unwanted effects.

How the process works

  1. Dose and metabolism
  2. Drug exposure
  3. Benefit and harm
Fluvoxamine can affect drug-processing enzymes as well as serotonin transport. Simplified illustration of the process; individual responses vary.
About this illustration

Dose and metabolism; Drug exposure; Benefit and harm. A drug level alone does not predict the overall balance of benefits and unwanted effects.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Nausea, sleep changes, restlessness and sexual effects can accompany treatment. Sexual symptoms sometimes persist after stopping.

How does my body process it?

It undergoes extensive liver metabolism. Repeated dosing gives a mean half-life around 17–22 hours; liver disease can reduce clearance.

How do treatment options differ?

Its enzyme inhibition makes the interaction profile distinct from other SSRIs; a shared class name does not imply interchangeability.

A closer look at the science

Receptor-binding studies show little direct binding at the major muscarinic, histamine, adrenergic and dopamine receptors assessed in the SmPC.

Fluvoxamine is an E-configured oxime compound supplied as a 1:1 maleate salt.

Chemical formula: C15H21F3N2O2 · C4H4O4

The verified image depicts neutral fluvoxamine, C15H21F3N2O2. Maleic acid is identified separately; the drawing does not show tablet or capsule release.

PubChem 2D depiction of neutral fluvoxamine; salt components omitted.
NCBI PubChem CID 5324346. Lines are bonds; unlabeled corners are carbon and many hydrogen atoms are omitted. This neutral-parent drawing is connectivity, not a binding pose.

The drawing shows the neutral parent. The product salt formula is separately identified; neither determines release rate or dose.

How was this medicine developed?

The Faverin 50 mg record lists June 2009 as its authorisation date. This is a product-record date, not the drug’s discovery.

Sources and References

  1. Faverin 50 mg Film-coated Tablets: UK SmPC — mechanism explanation

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: Mechanism explanation only. Source sections checked: 4.1 Therapeutic indications; 4.5 Interactions; 5.1 Pharmacodynamic properties; 5.2 Pharmacokinetic properties, Metabolism..

  2. Faverin 100 mg — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Faverin 50 and 100 mg — patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  4. Antidepressants: use and safety

    Scope: United Kingdom.

  5. Fluvoxamine maleate tablets prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 1 Indications and Usage; 7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes; 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics..

  6. What Is a Neurotransmitter? — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How Neurotransmitters Work; Types of Neurotransmitters..

  7. Fluvoxamine ER: current prescribing information

    Scope: Shared scientific explanation; source remains US, not UK prescribing authority.

  8. Fluvoxamine: verified neutral parent, PubChem CID 5324346

    Scope: International chemical reference.

  9. A qualitative investigation into the effects of akathisia - Health Research Authority
  10. Extrapyramidal side effects- Management
  11. Anxiety and panic attacks - NHS
  12. Agitation: MedlinePlus Medical Encyclopedia

Shared scientific background. US product pharmacology and chemical references do not establish UK licences, doses, formulations or NHS recommendations.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top